Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 8/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 5/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16818502 | 0.86 | ACLY (0.32) | SLC16A3MCTS1TACR1CA1CA2 | |
| SCHEMBL5672961 | 0.82 | SLC16A3 (0.33) | SLC16A3MCTS1SLC16A1 | |
| SCHEMBL16818604 | 0.82 | TACR1 (0.34) | SLC16A3MCTS1SLC16A1TACR1PKM | |
| SCHEMBL17803752 | 0.77 | ACLY (0.34) | SLC16A3MCTS1SLC16A1ACLY | |
| SCHEMBL19197241 | 0.74 | SMYD2 (0.38) | CA1CA2CA9CYP1A2CYP3A4 | |
| SCHEMBL31124766 | 0.74 | TSHR (0.35) | SLC16A3TACR1CYP3A4 | |
| SCHEMBL31124717 | 0.74 | TRPA1 (0.35) | TACR1CYP3A4 | |
| SCHEMBL1314001 | 0.73 | AGXT (0.42) | CYP3A4CYP2D6 | |
| SCHEMBL4426073 | 0.73 | IDO1 (0.48) | TACR1CA1CA2CA9 | |
| SCHEMBL22750792 | 0.72 | KDM4E (0.40) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | SLC16A3 4299/4885MCTS1 1515/4885SLC16A1 4291/4885 |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD1, BRD3, BRD2 | SLC16A3 4299/4885MCTS1 1515/4885SLC16A1 4291/4885 |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | SLC16A3 4299/4885MCTS1 1515/4885SLC16A1 4291/4885 |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | SLC16A3 4299/4885MCTS1 1515/4885SLC16A1 4291/4885 |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | SLC16A3 4299/4885MCTS1 1515/4885SLC16A1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.